Aptose Biosciences Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Aptose Biosciences Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($5.12M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($7.04M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($5.54M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($6.95M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($7.25M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($9.64M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($11.45M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($14.13M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($13.68M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($9.78M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($10.57M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($11.48M) | May 8, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($11.33M) | Nov 1, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($13.47M) | Aug 2, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($16.23M) | May 9, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($13.25M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($15.75M) | Aug 3, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($11.53M) | May 4, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($6.84M) | Nov 10, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($6.22M) | Aug 4, 2020 |